About: Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.63 (+21.05%)
GLMDNASDAQGalmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd share price
GLMD price activity
Last Price
$4.630
Change (24hr)
0.81 USD (21.05%)
Volume
290.36K
Volume (4w avg)
-
Open
$3.91
Day Range
$3.82 - $4.63
Previous Close
$3.83
Last Trade
09 Sep, 8:22 pm GMT+0
Delayed
09 Sep, 8:22 pm GMT+0
GLMD price performance
Delayed
09 Sep, 8:22 pm GMT+0
GLMD Market Signals